Evidence map›Paper›PMID 42743317›Full record

Trial reportCancer2026

Effect of demographic characteristics on the outcome of prostate cancer salvage radiotherapy: Analysis from a randomized controlled trial.

Ismaheel O Lawal, Ashesh B Jani, Subir Goyal, Olayinka Abiodun-Ojo, Vishal Dhere, Sarah Bell, Pretesh Patel, Bruce Hershatter, Krishna Chaudhary, Aliza Mushtaq and 8 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ismaheel O LawalDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-4273-040X
Ashesh B JaniDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Subir GoyalBiostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Olayinka Abiodun-OjoDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.
Vishal DhereDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Sarah BellDepartment of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-2611-3535
Pretesh PatelDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Bruce HershatterDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Krishna ChaudharyDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.
Aliza MushtaqDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.
Joseph SheltonDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Sheela HanasogeDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Nikhil SebastianDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-3977-7867
Sagar A PatelDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Raghuveer HalkarDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.
Viraj A MasterDepartment of Urology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Ruth C CarlosDepartment of Radiology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
David M SchusterDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, USA.

Funding

Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy RadiotherapyR01CA169188 · NCI · EMORY UNIVERSITY · PI JANI, ASHESH, SCHUSTER, DAVID MICHAEL · 2012 to 2016
$2.1M
Blue Earth Diagnostics, LimitedNCI NIH HHS R01 CA169188NIH HHS R01 CA169188Winship Cancer Institute of Emory University
6 · The paper itself

Abstract

backgroundThis study investigated the impact of advanced molecular imaging, race, socioeconomic status, and metabolic dysregulation on the outcome of salvage radiotherapy (sRT) for prostate cancer recurrence in a clinical trial setting.

methodsThe authors randomized post-prostatectomy men with detectable prostate-specific antigen to sRT guided by conventional imaging (arm A) or

resultsEighty-one (AAM = 29, MOR = 52) and 76 (AAM = 26, MOR = 50) men completed per-protocol sRT in arms A and B, respectively. Across study arms, AAM showed a higher FFS rate than MOR (72.8% [95% CI, 53.8%-85.0%] vs. 58.7% [95% CI, 46.6%-68.9%]; p = .002). In arm A, FFS rate was better for AAM than MOR, (64.0% [95% CI, 34.4%-82.9%] vs. 45.3% [95% CI, 28.8%-60.4%]; p = .008). In arm B, FFS improved for both groups but less so for AAM, (81.5% [95% CI, 57.2%-92.7%] vs. 73.0% [95% CI, 56.3%-84.1%]; p = .131). The authors found lower SES scores and higher AL scores for AAM in both study arms than MOR.

conclusionDespite lower socioeconomic status and higher burden of metabolic dysregulation, in a clinical trial setting that controls for disparities in health care access, AAM have a more favorable sRT outcome than MOR.

Indexed as

Neoplasm Recurrence, LocalProstatic NeoplasmsSalvage TherapyAgedBlack or African AmericanCarboxylic AcidsCyclobutanesDisease-Free SurvivalHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyProstatectomyProstate-Specific AntigenTreatment OutcomeCarboxylic AcidsCyclobutanesfluciclovine F-18Prostate-Specific Antigen18F‐fluciclovine PET/CTallostatic loadfailure‐free survivalprostate cancerrecurrencesalvage radiotherapysocioeconomic status index score

Identifiers

PMID42743317
PMCPMC13577497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.